First-line pemetrexed-platinum doublet chemotherapy with or without bevacizumab in non-squamous non-small cell lung cancer: A real-world propensity score-matched study in China

OBJECTIVE: To evaluate the efficacy and safety profile of first-line bevacizumab (Bev)-containing pemetrexed-platinum chemotherapy in a real-world Chinese cohort with advanced non-squamous non-small cell lung cancer (NS-NSCLC). METHODS: A total of 415 eligible patients with NS-NSCLC who received fir...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Fei, Hu, Xingsheng, Liu, Yutao, Wang, Zhijie, Duan, Jianchun, Wang, Jie, Dong, Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856705/
https://www.ncbi.nlm.nih.gov/pubmed/31814679
http://dx.doi.org/10.21147/j.issn.1000-9604.2019.05.05

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856705/
https://www.ncbi.nlm.nih.gov/pubmed/31814679
http://dx.doi.org/10.21147/j.issn.1000-9604.2019.05.05

Ejemplares similares